A Phase 1 Study to Evaluate the Safety and Tolerability of AB928, a Novel Dual Adenosine Receptor Antagonist, with AB122, a Programmed Cell Death-1 Inhibitor, in Patients with Advanced Malignancies


Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, CA 94545, USA

Abstract No. 10711

ABSTRACT

Background: In many tumors, extracellular adenosine contributes to an immunosuppressed tumor microenvironment via activation of the A2a receptor (A2aR) and A3 receptor (A3R) expressed on intratumoral immune cells. AB928 is a novel, selective, small-molecule antagonist of both A2aR and A3R with the ability to potently block the immunosuppressive effects of high concentrations of adenosine in the tumor microenvironment. Preclinically, combining adenosine receptor inhibition with either chemotherapy or anti-programmed cell death-1 resulted in greater tumor control in mouse models, suggesting that AB928 may have synergistic activity when paired with either chemotherapy or checkpoint inhibitors in oncology patients. A phase 1 study with AB928 in healthy volunteers has been completed. AB122 is a fully human monoclonal antibody targeting PD-1.

Methods: A phase 1, open-label, dose-escalation (3+3 design) study is evaluating the safety/tolerability (including dose-limiting toxicities [DLTs]), pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of AB928 in combination with AB122 in patients with advanced malignancies. Patients are eligible if they have pathologically confirmed non-small cell lung cancer, squamous cell carcinoma of the head and neck, renal cell carcinoma (RCC), breast cancer, colorectal cancer, melanoma, bladder cancer, ovarian cancer, endometrial cancer, Merkel cell carcinoma, or gastroesophageal cancer that is metastatic, advanced or recurrent with progression for which no alternative or curative therapy exists. Patients must have received standard of care (SOC), and may have received up to 5 lines of prior therapies. AB928 is administered orally once daily at a starting dose of 75 mg (Cohort 1) escalating to 150 mg (Cohort 2) and 200 mg (Cohort 3), and AB122 is administered intravenously (IV) every 2 weeks (Q2W) at 240 mg. Intermediate AB928 doses may be evaluated based on data from cohorts that have been explored; however, doses must not exceed the maximum tolerated dose (MTD). Following identification of the recommended phase 2 dose (RP2D) of AB928 and AB122 during dose escalation, select tumor cohorts may be expanded to further evaluate this combination. The primary endpoint is safety/tolerability and secondary endpoints are PK, PD (receptor occupancy in peripheral blood and immunomodulatory activity in select immune subsets), immunogenicity, and clinical activity (objective response rate [ORR], duration of response, disease control rate [DCR]; complete response [CR], partial response [PR], or stable disease [SD] for >6 months), and progression-free survival [PFS] per Response Evaluation Criteria in Solid Tumors [RECIST] v1.1, and overall survival. This study is recruiting.

BACKGROUND

The accumulation of adenosine, generated through hydrolysis of extracellular adenosine monophosphate (AMP) by the ectonucleoside triphosphate hydrolase CD73, is a key strategy exploited by tumors to escape immunosurveillance (Figure 1)1

- Adenosine’s suppressive effects on immune cells are driven primarily by 2 of the 4 adenosine receptors, A2aR and A3R.2
  - This effect is mediated by increased cyclic AMP (cAMP) levels and phosphorylation of cAMP response element binding protein (CREB)
- Pharmacological inhibition of the effects of adenosine has recently generated much interest in immuno-oncology, but thus far, only A2aR antagonists, initially developed for central nervous system indications,3 are being studied in oncology.

Figure 1. Adenosine-mediated immune suppression

- AB928 is a novel, selective, small-molecule A2aR/A3R antagonist designed to potently block the immunosuppressive effects of high concentrations of adenosine in the tumor microenvironment
- AB928 differs from other known A2aR antagonists based on its dual mode of action, its minimal loss of potency due to nonspecific binding to plasma proteins, and its lack of penetrance through a healthy blood-brain barrier
- Results from in vitro studies showed:5
  - AB928 blocked adenosine-mediated suppression of T-cell activation (ie, restored CD8 T-cell IFN-γ and CD4 T-cell IL-2 production, Figure 2)
  - AB928 inhibits adenosine-receptor-mediated increases in CREB
- In mouse models, combining adenosine receptor inhibition with either anti-PD-1 or chemotherapy resulted in greater tumor control, suggesting AB928 may have synergistic activity when combined with either checkpoint inhibitors or chemotherapy in cancer patients6

Figure 2. AB928 restores CD8 T-cell IFN-γ and CD4 T-cell IL-2 production

- A phase 1 study of AB928 in healthy volunteers has been completed6
  - This placebo-controlled study with single-ascending and multiple-ascending dose arms assessed AB928 doses between 10 and 200 mg once daily and 100 mg twice daily
  - AB928 was well tolerated and no safety concern was identified
    - All adverse events (AEs) were Grade 1-2; there were no DLTs, serious AEs, or AEs resulting in study drug discontinuation
    - The PK profile of AB928 was linear and dose-proportional, and a clear PK/PD correlation was demonstrated (Figure 3)
  - AB928 plasma levels ≥1 μM were associated with ≥90% adenosine receptor inhibition

Figure 3. PK/PD correlation in AB928-dosed subjects measured by pCREB inhibition

- Four clinical studies of AB928 in combination with other agents have been initiated in cancer patients in Australia and United States (Table 1)
  - The study described herein (AB928CS0005) is assessing the safety/tolerability, PK, PD, and clinical activity of AB928 in combination with AB122, a PD-1 inhibitor, in patients with advanced solid tumors

Table 1. Ongoing AB928 combination studies in oncology

Patients

- Key Inclusion Criteria
  - Male or female patients ≥18 years of age
  - Dose escalation: Pathologically confirmed non-small-cell lung cancer, squamous cell carcinoma of the head and neck, RCC, breast cancer, colorectal cancer, melanoma, bladder cancer, ovarian cancer, endometrial cancer, Merkel cell carcinoma, or gastroesophageal cancer that is metastatic, advanced or recurrent with progression for which no alternative or curative therapy exists
  - Dose expansion: Pathologically confirmed advanced clear-cell RCC previously treated with antiangiogenic and systemic regimens
    - ≥1 measurable lesion per RECIST v1.1
    - Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1
- Key Exclusion Criteria
  - Live vaccines within 4 weeks of study drug initiation
  - Pregnant or breastfeeding
  - Active or prior autoimmune disease requiring systemic treatment
  - Prior treatment with immune checkpoint inhibitor or agonist, or mTOR inhibitor

Methods

- Safety: Incidence of AEs and DLTs, and changes from baseline in vital signs, clinical laboratory parameters, physical examination findings, ECOG performance status, and electrocardiogram

Endpoints

Primary Endpoint

- Safety: Incidence of AEs and DLTs, and changes from baseline in vital signs, clinical laboratory parameters, physical examination findings, ECOG performance status, and electrocardiogram
- Secondary Endpoints
  - Serum concentration and PK parameters for AB928 combination therapy
  - Receptor occupancy in peripheral blood and immunomodulatory activity in select immune subsets for AB928 combination therapy
  - Clinical activity: ORR, duration of response, DCR (defined as CR, PR, or SD for >6 months), and PFS per RECIST v1.1, and overall survival

Statistical Analysis

- Summary statistics will be provided for AEs, serious AEs, AE severity, and relationship to study drug
- PK parameters will be estimated using noncompartmental methods
- DLT and DCR will be estimated by the proportion of patients with objective response and disease control, respectively, and their 95% confidence intervals will be estimated using the exact binomial method
- Time-to-event endpoints will be summarized using the Kaplan-Meier method
- Interim analyses for futility will be conducted for each expansion cohort that has enrolled ≥15 patients who are evaluable for disease assessment

Trial Status

- Enrollment is ongoing
- Clinicaltrials.gov NCT013629756

References